Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06306638 · ClinicalTrials.gov registry record · Phase 1

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

A Phase 1 study of Malignant Solid Neoplasm, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
Phase 1
Development phase
53
Enrollment target
2
Study locations

NCT06306638: Recruiting Phase 1 study of Malignant Solid Neoplasm, sponsored by Roswell Park Cancer Institute.

NCT06306638 is a Phase 1 study of Malignant Solid Neoplasm that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 53 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06306638, a Phase 1 study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
Phase 1
Development phase
53 participants
Enrollment target
2
Study locations

Study Summary

This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the patient at a higher risk for respiratory failure, post-obstructive pneumonia, and prolonged hospitalizations. Treatment for these patients may include bronchoscopic intervention (such as mechanical removal, stenting, laser cauterization, or ballooning), radiation therapy with and without chemotherapy. While palliative x-ray radiotherapy may help in shrinking the tumor, high dose curative radiotherapy that can ablate (a localized, nonsurgical destruction) the tumor also has high risk to cause significant toxicity, including bleeding, abnormal connections or passageways between organs or vessels and abnormal scar tissue that can also produce airway obstruction. Photodynamic therapy (PDT) is another possible treatment that can provide local control of the tumor. PDT consists of injecting a light sensitive drug (photosensitizer, PS) into the vein, waiting for the PS to accumulate in the tumor, and then activating it with a red laser light. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving interstitial photodynamic therapy following palliative radiotherapy may improve tumor response and survival without the serious side effects that are associated with the typical high dose curative x-ray radiotherapy alone in patients with malignant central airway obstruction.

Primary Outcome

Will will be associated with treatment related adverse events .grade 3 (with attribution of 'possible', 'probable' or 'definite'. Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).

Conditions Studied

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • RADIATION Palliative Radiation Therapy
  • PROCEDURE Endobronchial Ultrasound Bronchoscopy
  • PROCEDURE Interstitial Photodynamic Therapy

Study Locations (2)

New York

  • Roswell Park Cancer Institute - Buffalo

Pennsylvania

  • Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2024-10-01
Est. Completion 2029-10-01
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What NCT06306638 shows while recruiting

NCT06306638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06306638 reports a single indexed study location in New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06306638 about?

NCT06306638 is a clinical study titled "Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction". This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathi...

What is the current status of trial NCT06306638?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2024-10-01. Estimated completion is 2029-10-01.

What conditions does trial NCT06306638 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm.

What interventions are being tested in trial NCT06306638?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Palliative Radiation Therapy (RADIATION), Endobronchial Ultrasound Bronchoscopy (PROCEDURE), Interstitial Photodynamic Therapy (PROCEDURE).

Who is sponsoring clinical trial NCT06306638?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06306638 being conducted?

This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06306638's enrollment target sits among peer trials

53 123rd of 176 higher than 54 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04177004 · 53 participants · Phase 1

    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

  • NCT04199741 · 53 participants · Phase 1

    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

  • NCT04835129 · 53 participants · Phase 2

    Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

  • NCT04913805 · 53 participants · Phase 2

    Matching Perfusion and Metabolic Activity in HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06306638, the US trial registry maintained by the National Library of Medicine. NCT06306638 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.